An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \[IDH1m\]) and cannot receive treatment with intensive chemotherapy (IC).

Trial Details

NCT ID
NCT05907057
Phase
PHASE3
Sponsor
Servier Affaires Médicales
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ivosidenib 500mg Oral Tablet
  • Azacitidine
Locations (sample)
  • Vienna, Austria|48.20849,16.37208
  • Wels, Austria|48.16667,14.03333
  • Marseille, Bouches-du-Rhône, France|43.29695,5.38107
  • Caen, Calvados, France|49.18585,-0.35912
  • Toulouse, Haute Garonne, France|43.60426,1.44367

Key Eligibility Criteria

  • Has untreated Acute Myeloid Leukemia (AML)
  • Have a documented IDH1 R132 gene-mutated disease
  • Have at least one of the following making yourself ineligible for intensive chemotherapy (IC): 75 years or older, Eastern Cooperative Oncology Grou…
  • Has adequate hepatic (liver) and renal (kidney) function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →